TurkeyTuberculosis profile
Population  2016 80 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.48 (0.35–0.63) 0.61 (0.44–0.79)
Mortality (HIV+TB only) 0.015 (0.011–0.02) 0.02 (0.01–0.02)
Incidence  (includes HIV+TB) 14 (12–16) 18 (15–20)
Incidence (HIV+TB only) 0.092 (0.077–0.11) 0.12 (0.1–0.14)
Incidence (MDR/RR-TB)** 0.56 (0.46–0.65) 0.7 (0.58–0.82)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.7 (0.6–0.81) 5.3 (4.5–6.1) 6 (5.1–6.9)
Males 0.79 (0.67–0.91) 7.2 (6.1–8.3) 8 (6.8–9.2)
Total 1.5 (1.3–1.7) 13 (11–14) 14 (12–16)
TB case notifications, 2016  
Total cases notified 12 417
Total new and relapse 12 186
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 70%
          - % pulmonary 66%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.04 (0.03–0.05)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 56 <1%
          - on antiretroviral therapy 51 91%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  350
(300–390)
Estimated % of TB cases with MDR/RR-TB 2.9% (2.5–3.4) 16% (13–19)  
% notified tested for rifampicin resistance 48% 62% 6 051
MDR/RR-TB cases tested for resistance to second-line drugs   162
Laboratory-confirmed cases MDR/RR-TB: 256, XDR-TB: 9
Patients started on treatment **** MDR/RR-TB: 217, XDR-TB: 9
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 87% 12 362
Previously treated cases, excluding relapse, registered in 2015 46% 158
HIV-positive TB cases registered in 2015 58% 57
MDR/RR-TB cases started on second-line treatment in 2014 63% 257
XDR-TB cases started on second-line treatment in 2014 0% 2
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data